0.382USD+0.382After-hours 07/31, 20:00 (ET)
2.12MMarket Cap
LossP/E TTM
Key Figures
0.880Open
1.069High
19.31MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
361.88%Turnover Ratio
1.020Prev. Close
0.312Low
5.48MTurnover
LossP/E Static
0.14P/B
0.00%Div Yield TTM
-182.54%ROA
24.00052wk High
27.12Volume Ratio
-21.76MNet Profit
5.34MShares
-16.1644EPS TTM
1.76Beta
-556.58%ROE
1.79052wk Low
74.19%Amplitude
--Gross Margin
2.12MMarket Cap
-10.90Reward/Risk
5.63%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Moleculin Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Moleculin Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Moleculin Biotech Inc Highlights
StrengthsRisks
Moleculin Biotech Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Moleculin Biotech Inc
MBRX
3
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Moleculin Biotech Inc Info
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Ticker SymbolMBRX
CompanyMoleculin Biotech Inc
CEOKlemp (Walter V)
Websitehttps://moleculin.com/
Shareholders
FAQs
What is the current price of Moleculin Biotech Inc (MBRX)?
The current price of Moleculin Biotech Inc (MBRX) is 0.40.
What is the symbol of Moleculin Biotech Inc?
The ticker symbol of Moleculin Biotech Inc is MBRX.
What is the 52-week high of Moleculin Biotech Inc?
The 52-week high of Moleculin Biotech Inc is 24.00.
What is the 52-week low of Moleculin Biotech Inc?
The 52-week low of Moleculin Biotech Inc is 1.79.
What is the market capitalization of Moleculin Biotech Inc?
The market capitalization of Moleculin Biotech Inc is 2.12M.
Is Moleculin Biotech Inc (MBRX) currently rated as Buy, Hold, or Sell?
According to analysts, Moleculin Biotech Inc (MBRX) has an overall rating of Buy, with a price target of 21.00.
What is the Earnings Per Share (EPS TTM) of Moleculin Biotech Inc (MBRX)?
The Earnings Per Share (EPS TTM) of Moleculin Biotech Inc (MBRX) is -28.42.
